{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T18:48:26Z","timestamp":1775328506354,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T00:00:00Z","timestamp":1623110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T00:00:00Z","timestamp":1623110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1038\/s41401-021-00682-9","type":"journal-article","created":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T08:03:10Z","timestamp":1623139390000},"page":"1235-1247","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Inhibition of Nav1.7 channel by a novel blocker QLS-81 for alleviation of neuropathic pain"],"prefix":"10.1038","volume":"42","author":[{"given":"He-ling","family":"Niu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-ni","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deng-qi","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-ying","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-lin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An-ruo","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-ming","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KeWei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,8]]},"reference":[{"key":"682_CR1","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.drudis.2019.05.014","volume":"24","author":"L Xu","year":"2019","unstructured":"Xu L, Ding X, Wang T, Mou S, Sun H, Hou T. Voltage-gated sodium channels: structures, functions, and molecular modeling. Drug Discov Today. 2019;24:1389\u201397.","journal-title":"Drug Discov Today"},{"key":"682_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1795","volume":"3","author":"MS Minett","year":"2012","unstructured":"Minett MS, Nassar MA, Clark AK, Passmore G, Dickenson AH, Wang F, et al. Distinct Nav1.7-dependent pain sensations require different sets of sensory and sympathetic neurons. Nat Commun. 2012;3:791.","journal-title":"Nat Commun"},{"key":"682_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nrneurol.2010.162","volume":"7","author":"JS Choi","year":"2011","unstructured":"Choi JS, Boralevi F, Brissaud O, Sanchez-Martin J, Te Morsche RH, Dib-Hajj SD, et al. Paroxysmal extreme pain disorder: a molecular lesion of peripheral neurons. Nat Rev Neurol. 2011;7:51\u20135.","journal-title":"Nat Rev Neurol"},{"key":"682_CR4","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1086\/320609","volume":"68","author":"L Claes","year":"2001","unstructured":"Claes L, Del-Favero J, Ceulemans B, Lagae L, Van Broeckhoven C, De Jonghe P. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet. 2001;68:1327\u201332.","journal-title":"Am J Hum Genet"},{"key":"682_CR5","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/ana.24580","volume":"79","author":"E Gardella","year":"2016","unstructured":"Gardella E, Becker F, Moller RS, Schubert J, Lemke JR, Larsen LH, et al. Benign infantile seizures and paroxysmal dyskinesia caused by an SCN8A mutation. Ann Neurol. 2016;79:428\u201336.","journal-title":"Ann Neurol"},{"key":"682_CR6","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/164_2019_333","volume":"260","author":"Y Liu","year":"2019","unstructured":"Liu Y, Wang K. Exploiting the diversity of ion channels: modulation of ion channels for therapeutic indications. Handb Exp Pharmacol. 2019;260:187\u2013205.","journal-title":"Handb Exp Pharmacol"},{"key":"682_CR7","doi-asserted-by":"publisher","first-page":"e0152405","DOI":"10.1371\/journal.pone.0152405","volume":"11","author":"AJ Alexandrou","year":"2016","unstructured":"Alexandrou AJ, Brown AR, Chapman ML, Estacion M, Turner J, Mis MA, et al. Subtype-selective small molecule inhibitors reveal a fundamental role for Nav1.7 in nociceptor electrogenesis, axonal conduction and presynaptic release. PLoS One 2016;11:e0152405.","journal-title":"PLoS One"},{"key":"682_CR8","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrn3404","volume":"14","author":"SD Dib-Hajj","year":"2013","unstructured":"Dib-Hajj SD, Yang Y, Black JA, Waxman SG. The Na(V)1.7 sodium channel: from molecule to man. Nat Rev Neurosci. 2013;14:49\u201362.","journal-title":"Nat Rev Neurosci"},{"key":"682_CR9","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.neuron.2006.10.006","volume":"52","author":"CR Fertleman","year":"2006","unstructured":"Fertleman CR, Baker MD, Parker KA, Moffatt S, Elmslie FV, Abrahamsen B, et al. SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuron. 2006;52:767\u201374.","journal-title":"Neuron"},{"key":"682_CR10","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.molmed.2005.10.004","volume":"11","author":"SG Waxman","year":"2005","unstructured":"Waxman SG, Dib-Hajj S. Erythermalgia: molecular basis for an inherited pain syndrome. Trends Mol Med. 2005;11:555\u201362.","journal-title":"Trends Mol Med"},{"key":"682_CR11","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1136\/jmg.2003.012153","volume":"41","author":"Y Yang","year":"2004","unstructured":"Yang Y, Wang Y, Li S, Xu Z, Li H, Ma L, et al. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J Med Genet. 2004;41:171\u20134.","journal-title":"J Med Genet"},{"key":"682_CR12","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s00424-020-02419-9","volume":"472","author":"MD Baker","year":"2020","unstructured":"Baker MD, Nassar MA. Painful and painless mutations of SCN9A and SCN11A voltage-gated sodium channels. Pflug Arch. 2020;472:865\u201380.","journal-title":"Pflug Arch"},{"key":"682_CR13","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1038\/nature05413","volume":"444","author":"JJ Cox","year":"2006","unstructured":"Cox JJ, Reimann F, Nicholas AK, Thornton G, Roberts E, Springell K, et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature. 2006;444:894\u20138.","journal-title":"Nature"},{"key":"682_CR14","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1113\/jphysiol.2010.200915","volume":"589","author":"JW Theile","year":"2011","unstructured":"Theile JW, Jarecki BW, Piekarz AD, Cummins TR. Nav1.7 mutations associated with paroxysmal extreme pain disorder, but not erythromelalgia, enhance Navbeta4 peptide-mediated resurgent sodium currents. J Physiol. 2011;589:597\u2013608.","journal-title":"J Physiol"},{"key":"682_CR15","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.neuron.2019.01.047","volume":"101","author":"LA McDermott","year":"2019","unstructured":"McDermott LA, Weir GA, Themistocleous AC, Segerdahl AR, Blesneac I, Baskozos G, et al. Defining the functional role of NaV1.7 in human nociception. Neuron. 2019;101:905\u201319.e8.","journal-title":"Neuron"},{"key":"682_CR16","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/bs.podrm.2015.11.001","volume":"41","author":"ST Alrashood","year":"2016","unstructured":"Alrashood ST. Carbamazepine. Profiles Drug Subst Excip Relat Methodol. 2016;41:133\u2013321.","journal-title":"Profiles Drug Subst Excip Relat Methodol"},{"key":"682_CR17","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.bja.2019.06.014","volume":"123","author":"H Hermanns","year":"2019","unstructured":"Hermanns H, Hollmann MW, Stevens MF, Lirk P, Brandenburger T, Piegeler T, et al. Molecular mechanisms of action of systemic lidocaine in acute and chronic pain: a narrative review. Br J Anaesth. 2019;123:335\u201349.","journal-title":"Br J Anaesth"},{"key":"682_CR18","unstructured":"Singh S, Kerndt C, Zeltser R. Mexiletine. In: StatPearls. FL: Treasure Island; 2020."},{"key":"682_CR19","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1053\/rapm.2002.37326","volume":"27","author":"MF Mulroy","year":"2002","unstructured":"Mulroy MF. Systemic toxicity and cardiotoxicity from local anesthetics: incidence and preventive measures. Reg Anesth Pain Med. 2002;27:556\u201361.","journal-title":"Reg Anesth Pain Med"},{"key":"682_CR20","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1073\/pnas.1817446116","volume":"116","author":"PT Nguyen","year":"2019","unstructured":"Nguyen PT, DeMarco KR, Vorobyov I, Clancy CE, Yarov-Yarovoy V. Structural basis for antiarrhythmic drug interactions with the human cardiac sodium channel. Proc Natl Acad Sci USA. 2019;116:2945\u201354.","journal-title":"Proc Natl Acad Sci USA"},{"key":"682_CR21","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1021\/acs.jmedchem.8b01621","volume":"62","author":"S Sun","year":"2019","unstructured":"Sun S, Jia Q, Zenova AY, Wilson MS, Chowdhury S, Focken T, et al. Identification of selective acyl sulfonamide-cycloalkylether inhibitors of the voltage-gated sodium channel (Nav) 1.7 with potent analgesic activity. J Med Chem. 2019;62:908\u201327.","journal-title":"J Med Chem"},{"key":"682_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ejphar.2018.01.041","volume":"823","author":"X Liang","year":"2018","unstructured":"Liang X, Yu G, Su R. Effects of ralfinamide in models of nerve injury and chemotherapy-induced neuropathic pain. Eur J Pharmacol. 2018;823:27\u201334.","journal-title":"Eur J Pharmacol"},{"key":"682_CR23","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ejphar.2005.01.030","volume":"510","author":"TC Stummann","year":"2005","unstructured":"Stummann TC, Salvati P, Fariello RG, Faravelli L. The anti-nociceptive agent ralfinamide inhibits tetrodotoxin-resistant and tetrodotoxin-sensitive Na+ currents in dorsal root ganglion neurons. Eur J Pharmacol. 2005;510:197\u2013208.","journal-title":"Eur J Pharmacol"},{"key":"682_CR24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/s0304-3959(02)00183-5","volume":"102","author":"O Veneroni","year":"2003","unstructured":"Veneroni O, Maj R, Calabresi M, Faravelli L, Fariello RG, Salvati P. Anti-allodynic effect of NW-1029, a novel Na+ channel blocker, in experimental animal models of inflammatory and neuropathic pain. Pain. 2003;102:17\u201325.","journal-title":"Pain"},{"key":"682_CR25","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.pain.2008.04.020","volume":"139","author":"SH Zhang","year":"2008","unstructured":"Zhang SH, Blech-Hermoni Y, Faravelli L, Seltzer Z. Ralfinamide administered orally before hindpaw neurectomy or postoperatively provided long-lasting suppression of spontaneous neuropathic pain-related behavior in the rat. Pain. 2008;139:293\u2013305.","journal-title":"Pain"},{"key":"682_CR26","doi-asserted-by":"publisher","first-page":"S152","DOI":"10.1016\/j.ejpain.2007.03.359","volume":"11","author":"E Colombo","year":"2007","unstructured":"Colombo E, Curatolo L, Caccia C, Salvati P, Faravelli L. 344 ralfinamide acts through nmda receptor complex: a central role for chronic pain treatment. Eur J Pain. 2007;11:S152\u2013S3.","journal-title":"Eur J Pain"},{"key":"682_CR27","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1016\/j.pain.2014.08.025","volume":"155","author":"X Du","year":"2014","unstructured":"Du X, Hao H, Gigout S, Huang D, Yang Y, Li L, et al. Control of somatic membrane potential in nociceptive neurons and its implications for peripheral nociceptive transmission. Pain. 2014;155:2306\u201322.","journal-title":"Pain"},{"key":"682_CR28","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1023\/A:1022902006434","volume":"23","author":"PL Andersen","year":"2003","unstructured":"Andersen PL, Doucette JR, Nazarali AJ. A novel method of eliminating non-neuronal proliferating cells from cultures of mouse dorsal root ganglia. Cell Mol Neurobiol. 2003;23:205\u201310.","journal-title":"Cell Mol Neurobiol"},{"key":"682_CR29","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.pain.2005.10.036","volume":"122","author":"AF Bourquin","year":"2006","unstructured":"Bourquin AF, Suveges M, Pertin M, Gilliard N, Sardy S, Davison AC, et al. Assessment and analysis of mechanical allodynia-like behavior induced by spared nerve injury (SNI) in the mouse. Pain. 2006;122:14.","journal-title":"Pain"},{"key":"682_CR30","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jphs.2017.08.007","volume":"135","author":"X Wang","year":"2017","unstructured":"Wang X, Zhang G, Qiao Y, Feng C, Zhao X. Crocetin attenuates spared nerve injury-induced neuropathic pain in mice. J Pharmacol Sci. 2017;135:141\u20137.","journal-title":"J Pharmacol Sci"},{"key":"682_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/1744-8069-10-26","volume":"10","author":"RP Bonin","year":"2014","unstructured":"Bonin RP, Bories C, De, Koninck Y. A simplified up-down method (SUDO) for measuring mechanical nociception in rodents using von Frey filaments. Mol Pain. 2014;10:26.","journal-title":"Mol Pain"},{"key":"682_CR32","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/978-1-4939-7571-6_28","volume":"1727","author":"S Boccella","year":"2018","unstructured":"Boccella S, Guida F, Palazzo E, Marabese I, de Novellis V, Maione S, et al. Spared nerve injury as a long-lasting model of neuropathic pain. Methods Mol Biol. 2018;1727:373\u20138.","journal-title":"Methods Mol Biol"},{"key":"682_CR33","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.brainres.2017.01.011","volume":"1658","author":"LR Harton","year":"2017","unstructured":"Harton LR, Richardson JR, Armendariz A, Nazarian A. Dissociation of morphine analgesic effects in the sensory and affective components of formalin-induced spontaneous pain in male and female rats. Brain Res. 2017;1658:36\u201341.","journal-title":"Brain Res"},{"key":"682_CR34","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.3389\/fphar.2018.01158","volume":"9","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Peng D, Huang B, Yang Q, Zhang Q, Chen M, et al. Discovery of a novel Nav1.7 inhibitor from cyriopagopus albostriatus venom with potent analgesic efficacy. Front Pharmacol. 2018;9:1158.","journal-title":"Front Pharmacol"},{"key":"682_CR35","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1177\/1074248418791999","volume":"24","author":"B Qiu","year":"2019","unstructured":"Qiu B, Wang Y, Li C, Guo H, Xu Y. Utility of the JT peak interval and the JT area in determining the proarrhythmic potential of QT-shortening agents. J Cardiovasc Pharmacol Ther. 2019;24:160\u201371.","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"682_CR36","doi-asserted-by":"publisher","first-page":"e0128653","DOI":"10.1371\/journal.pone.0128653","volume":"10","author":"Y Wang","year":"2015","unstructured":"Wang Y, Mi J, Lu K, Lu Y, Wang K. Comparison of gating properties and use-dependent block of Nav1.5 and Nav1.7 channels by anti-arrhythmics mexiletine and lidocaine. PLoS One. 2015;10:e0128653.","journal-title":"PLoS One"},{"key":"682_CR37","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/bs.ctm.2016.04.001","volume":"78","author":"MR Ghovanloo","year":"2016","unstructured":"Ghovanloo MR, Aimar K, Ghadiry-Tavi R, Yu A, Ruben PC. Physiology and pathophysiology of sodium channel inactivation. Curr Top Membr. 2016;78:479\u2013509.","journal-title":"Curr Top Membr"},{"key":"682_CR38","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nature04710","volume":"440","author":"MC Sanguinetti","year":"2006","unstructured":"Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature. 2006;440:463\u20139.","journal-title":"Nature"},{"key":"682_CR39","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00424-010-0814-4","volume":"460","author":"K Jurkat-Rott","year":"2010","unstructured":"Jurkat-Rott K, Holzherr B, Fauler M, Lehmann-Horn F. Sodium channelopathies of skeletal muscle result from gain or loss of function. Pflug Arch. 2010;460:239\u201348.","journal-title":"Pflug Arch"},{"key":"682_CR40","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1080\/19336950.2019.1600967","volume":"13","author":"S Huang","year":"2019","unstructured":"Huang S, Zhang W, Chang X, Guo J. Overlap of periodic paralysis and paramyotonia congenita caused by SCN4A gene mutations two family reports and literature review. Channels. 2019;13:110\u20139.","journal-title":"Channels"},{"key":"682_CR41","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s00246-012-0303-y","volume":"33","author":"W Song","year":"2012","unstructured":"Song W, Shou W. Cardiac sodium channel Nav1.5 mutations and cardiac arrhythmia. Pediatr Cardiol. 2012;33:943\u20139.","journal-title":"Pediatr Cardiol"},{"key":"682_CR42","doi-asserted-by":"publisher","first-page":"aac5464","DOI":"10.1126\/science.aac5464","volume":"350","author":"S Ahuja","year":"2015","unstructured":"Ahuja S, Mukund S, Deng L, Khakh K, Chang E, Ho H, et al. Structural basis of Nav1.7 inhibition by an isoform-selective small-molecule antagonist. Science. 2015;350:aac5464.","journal-title":"Science"},{"key":"682_CR43","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.tips.2009.12.007","volume":"31","author":"F Bosmans","year":"2010","unstructured":"Bosmans F, Swartz KJ. Targeting voltage sensors in sodium channels with spider toxins. Trends Pharmacol Sci. 2010;31:175\u201382.","journal-title":"Trends Pharmacol Sci"},{"key":"682_CR44","doi-asserted-by":"publisher","first-page":"7093","DOI":"10.1021\/jm501981g","volume":"58","author":"M de Lera Ruiz","year":"2015","unstructured":"de Lera Ruiz M, Kraus RL. Voltage-gated sodium channels: structure, function, pharmacology, and clinical indications. J Med Chem. 2015;58:7093\u2013118.","journal-title":"J Med Chem"},{"key":"682_CR45","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1021\/jm501765v","volume":"58","author":"JK Murray","year":"2015","unstructured":"Murray JK, Ligutti J, Liu D, Zou A, Poppe L, Li H, et al. Engineering potent and selective analogues of GpTx-1, a tarantula venom peptide antagonist of the Nav1.7 sodium channel. J Med Chem. 2015;58:2299\u2013314.","journal-title":"J Med Chem"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41401-021-00682-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41401-021-00682-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41401-021-00682-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:03:54Z","timestamp":1684616634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00682-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,8]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["682"],"URL":"https:\/\/doi.org\/10.1038\/s41401-021-00682-9","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,8]]},"assertion":[{"value":"28 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}